Study summary · research use only
Thymosin alpha 1 treatment for patients with sepsis
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This review discusses thymosin alpha 1 (Tα1), described as acting as an immune modulator, in relation to sepsis, drawing on clinical studies collected from English and Chinese databases in human patients with sepsis or septic shock. It reports that in previous studies, single or combined treatment with Tα1 was associated with reduced mortality rate of sepsis, improved expression of HLA-DR on monocytes, and a diminished incidence of secondary infection. The authors describe Tα1 as a potential adjuvant therapy for sepsis, while noting that sepsis is a heterogeneous clinical syndrome such that results cannot be generalized to all septic patients, and that existing studies have not focused on immunosuppressed individuals specifically, which the authors suggest future trials should address.
Abstract
Sepsis is a life-threatening organ dysfunction caused by host immune response to infection. In this regard, modifying host immune response may help to eliminate systemic infection and restore organ function. Thymosin alpha 1 (Tα1), acting as an immune modulator, exerts great biological influence in activating and restoring the dysregulated immune response for patients with sepsis. In this review, we summarize the clinical studies of Tα1 treatment alone and in combination with anti-inflammatory for patients with sepsis or septic shock. Clinical studies were collected from available English and Chinese databases. In previous studies, single or combined treatment with Tα1 reduced the mortality rate of sepsis, improved the expression of HLA-DR on monocyte, and diminished the incidence of secondary infection. Based on the existing studies, Tα1 seems to be a promising alternative adjuvant therapy for sepsis. However, sepsis is a remarkably heterogeneous clinical syndrome, so much so that it is impossible to generalize the clinical results to all septic patients. Also, the present studies on Tα1 treatment are not able to focus on the immunosuppressive individuals. We believe that selecting septic patients with immunosuppression will be more likely to reveal the efficacy of Tα1 in future trials.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.